How does A268600's PS Ratio compare to its peers?

A268600 is good value based on its Price-To-Sales Ratio (10.9x) compared to the peer average (16.2x).

How does A268600's PS Ratio compare vs other companies in the KR Life Sciences Industry?

A268600 is expensive based on its Price-To-Sales Ratio (10.9x) compared to the KR Life Sciences industry average (3.4x).

What is A268600's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate A268600's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of A268600 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate A268600's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

A268600 Stock Overview

Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening diseases comprising cancer, inflammation, metabolic, and neurodegenerative diseases. More details

A268600 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Earnings have declined by 42.7% per year over past 5 years

Negative shareholders equity

Shares are highly illiquid

Has less than 1 year of cash runway

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Cellivery Therapeutics, Inc. Competitors

Curiox Biosystems

KOSDAQ:A445680

₩298.8b

FutureChemLtd

KOSDAQ:A220100

₩382.5b

HLB bioStepLtd

KOSDAQ:A278650

₩176.4b

Macrogen

KOSDAQ:A038290

₩164.5b

Price History & Performance

Summary of share price highs, lows and changes for Cellivery Therapeutics
Historical stock prices
Current Share Price	₩6,680.00
52 Week High	₩20,900.00
52 Week Low	₩6,680.00
Beta	0.50
1 Month Change	0%
3 Month Change	-29.91%
1 Year Change	-45.36%
3 Year Change	-74.58%
5 Year Change	n/a
Change since IPO	-6.90%

Recent updates

Shareholder Returns

	A268600	KR Life Sciences	KR Market
7D	0%	1.5%	-1.5%
1Y	-45.4%	22.9%	-10.9%

Return vs Industry: A268600 underperformed the KR Life Sciences industry which returned -13% over the past year.

Return vs Market: A268600 underperformed the KR Market which returned 8% over the past year.

Price Volatility

Is A268600's price volatile compared to industry and market?
A268600 volatility
A268600 Average Weekly Movement	n/a
Life Sciences Industry Average Movement	10.2%
Market Average Movement	6.6%
10% most volatile stocks in KR Market	12.8%
10% least volatile stocks in KR Market	3.4%

Stable Share Price: A268600's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine A268600's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2014	100	Daewoong Jo	www.cellivery.com

Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening diseases comprising cancer, inflammation, metabolic, and neurodegenerative diseases. It develops small molecule, antibody, and vaccine drugs based on its therapeutic molecule systemic delivery technology. The company was incorporated in 2014 and is based in Seoul, South Korea.

Cellivery Therapeutics, Inc. Fundamentals Summary

How do Cellivery Therapeutics's earnings and revenue compare to its market cap?
A268600 fundamental statistics
Market cap	₩244.94b
Earnings (TTM)	-₩73.70b
Revenue (TTM)	₩22.57b

10.9x

P/S Ratio

-3.3x

P/E Ratio

Is A268600 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A268600 income statement (TTM)
Revenue	₩22.57b
Cost of Revenue	₩23.15b
Gross Profit	-₩578.02m
Other Expenses	₩73.12b
Earnings	-₩73.70b

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.01k
Gross Margin	-2.56%
Net Profit Margin	-326.54%
Debt/Equity Ratio	-979.5%

How did A268600 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/06/20 04:27
End of Day Share Price	2023/03/23 00:00
Earnings	2023/03/31
Annual Earnings	2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cellivery Therapeutics, Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution